LB Pharmaceuticals Inc (LBRX)

LB Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-18.8	-63.1	-6.28	-14.35
Depreciation & Amortization	0.32	0.09	0	0
Other Amortization	-	3.22	3.88	1.64
Loss (Gain) From Sale of Investments	-0.3	-0.99	0.1	-0
Stock-Based Compensation	4.13	3.16	0.3	0.43
Other Operating Activities	-1.14	1.26	-8.79	9.46
Change in Accounts Payable	-5.8	5.02	1.1	0.13
Change in Other Net Operating Assets	-1.17	-1.7	-2.41	-0.05
Operating Cash Flow	-22.77	-53.05	-12.09	-2.73
Capital Expenditures	-0.25	-0.77	-0.03	-
Investment in Securities	-26.06	24	-27.99	0.12
Investing Cash Flow	-26.31	23.23	-28.01	0.12
Long-Term Debt Issued	-	-	0.73	25.01
Net Debt Issued (Repaid)	-	-	0.73	25.01
Issuance of Common Stock	328	0.02	0	-
Other Financing Activities	-24.27	-1.71	-2.05	-2.95
Financing Cash Flow	303.73	38.32	33.68	22.96
Net Cash Flow	254.65	8.5	-6.43	20.36
Free Cash Flow	-23.02	-53.82	-12.12	-2.73
Free Cash Flow Per Share	-0.91	-213.75	-48.55	-11.80
Cash Interest Paid	-	-	1.98	-
Cash Income Tax Paid	0	0	0	0
Levered Free Cash Flow	-	-28.34	-6.09	-
Unlevered Free Cash Flow	-	-28.34	-6.96	-
Change in Working Capital	-6.97	3.31	-1.31	0.09

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q